Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.98 ^USD	+5.15%		+3.22%	+46.25%

Apr. 01	Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	MT
Apr. 01	Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	DJ

Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 13, 2024 at 07:31 am EDT

Solid Biosciences Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 96.02 million compared to USD 85.98 million a year ago. Basic loss per share from continuing operations was USD 4.83 compared to USD 10.1 a year ago.

Latest news about Solid Biosciences Inc.

Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	Apr. 01	MT
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	Apr. 01	DJ
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Apr. 01	CI
William Blair Starts Solid Biosciences With Outperform Rating	Mar. 28	MT
Barclays Adjusts Price Target on Solid Biosciences to $21 From $8, Maintains Overweight Rating	Mar. 18	MT
Citigroup Starts Coverage on Solid Biosciences With Buy Rating, $16 Price Target	Mar. 15	MT
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Piper Sandler Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $20 From $8	Mar. 14	MT
Transcript : Solid Biosciences Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
HC Wainwright Adjusts Solid Biosciences' PT to $16 From $9, Maintains Buy Rating	Mar. 11	MT
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	Mar. 07	CI
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	Jan. 16	MT
Solid Biosciences Gets Orphan Drug Designation for SGT-003	Jan. 16	DJ
Transcript : Solid Biosciences Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	Jan. 11
Top Midday Gainers	Jan. 09	MT
Solid Biosciences Shares Surge After Revealing $109 Million Private Placement	Jan. 09	MT
Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors	Jan. 07	CI
Solid Biosciences Shares Fall After Surging Thursday; HC Wainwright Starts Coverage With Buy Rating	Dec. 08	MT
HC Wainwright Initiates Solid Biosciences With Buy Rating, Price Target is $9	Dec. 08	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	Dec. 07	MT
Top Midday Gainers	Dec. 07	MT
Solid Biosciences Says FDA Grants Fast Track Designation to Duchenne Muscular Dystrophy Gene Therapy; Shares Rise	Dec. 07	MT
Solid Biosciences Shares Jump After FDA Fast-Tracks SGT-0003	Dec. 07	DJ
Wall Street Set to Extend Rally on Back of Cooling Inflation, Driving Premarket Gains for US Equity Futures	Nov. 15	MT

Chart Solid Biosciences Inc.

Duration

Period

More charts

Company Profile

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.98 USD

Average target price

17.78 USD

Spread / Average Target

+97.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOLID BIOSCIENCES INC.	+46.25%	339M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs